Localized primary amyloidosis of the breast: a case report and review of the literature

Wakako Tsuji1*, Eiji Takeuchi2, Satoshi Oka3, Taro Yamashita4 and Fumiaki Yotsumoto1

Abstract

Background: Primary amyloidosis of the breast is an unusual benign disease that mostly occurs in postmenopausal elderly women. Amyloidosis is the deposition of amorphous protein within tissues. Breast biopsy is necessary to make a definite diagnosis in order to avoid unnecessary surgical methods. Localized primary amyloidosis of the breast has a good prognosis. However, secondary amyloidosis is a systemic disease and has a poor prognosis.

Case presentation: We report the case of a 77-year-old female with primary amyloidosis of the breast. She noticed a lump in her left breast. Mammographic and ultrasonographic examinations indicated breast cancer. However, core needle biopsy showed amyloidosis, not cancer of the breast. For further examinations, the patient visited the outpatient clinics of the hematology, dermatology, and gastroenterology departments. She underwent bone marrow aspiration, computed tomography, cardiac ultrasonography, random skin biopsy, gastrofiberscopy, and colonofiberscopy. Plasma cell myeloma and systemic amyloidosis were ruled out, and localized breast amyloidosis was highly suspected. Lumpectomy was performed to make a definite diagnosis, and histological evaluations revealed that this patient had localized amyloidosis of the breast, and the deposited amyloid protein was of the amyloid light chain kappa type.

Conclusions: Breast biopsy is necessary in order to avoid unnecessary surgical technique. A diagnosis should be achieved only through a histological evaluation. The main treatment of localized primary amyloidosis of the breast is surgical removal.

Keywords: Primary amyloidosis of the breast, Congo red, ALk, Amyloid, Breast cancer

Background

Amyloidosis of the breast is a very rare disease. We experienced a case of primary amyloidosis of the breast for the first time in 27 years at our institution. Amyloidosis of the breast was first reported in 1973 [1], and most of the reported cases involved postmenopausal elderly women. Breast amyloidosis can be a part of a systemic disease or may be localized to the breast. Furthermore, amyloidosis of the breast is reported to be often associated with an underlying breast cancer [2].

Primary amyloidosis of the breast typically presents with a painless and palpable mass [3]. The common mammographic findings of breast amyloidosis are multiple nodules with or without calcifications [2, 4–6].

O’Brien et al. reported that amyloidosis of the breast demonstrates low signal intensity on T1-weighed magnetic resonance imaging (MRI) and high signal intensity on T2-weighted MRI [7]. Reports on ultrasonographic findings of breast amyloidosis are rare [8].

Breast amyloidosis typically appears as diffuse breast involvement in the systemic form of amyloidosis, however, this condition can also be localized to the breast only. A study from the Mayo Clinic reviewed 40 cases of amyloidosis of the breast, and demonstrated that systemic amyloidosis accounted for nearly 50 % of all cases [3]. Moreover, concurrent hematologic malignancies were found in association with amyloidosis of the breast in 55 % of all patients.

Amyloidosis is classified as (i) primary amyloidosis and amyloidosis related to multiple myeloma (light chain amyloidosis [AL]), (ii) secondary amyloidosis (amyloid A
amyloidosis [AA]), or (iii) familial amyloidosis (amyloidogenic transthyretin [ATTR]) on the basis of the chemical composition of the tumors. The most common type of amyloid is AL. The kappa light chain type is more frequently found than the lambda light chain type. Secondary amyloidosis is characterized by the deposition of the acute-phase protein serum amyloid A (SAA). Secondary amyloidosis is caused by an underlying chronic inflammatory disease such as rheumatoid arthritis or a malignant tumor. AA amyloid disappears after permanganic acid treatment. Familial amyloid polyneuropathy is one type of hereditary generalized amyloidosis. This disease is caused by a mutation in the *transthyretin* (*TTR*) gene, with the ATTR type being usually identified.

Breast biopsy is necessary to make a definite diagnosis of amyloidosis of the breast, in order to avoid unnecessary surgical interventions. Localized primary amyloidosis of the breast has a good prognosis. However, secondary amyloidosis is caused by a systemic disease and has a poor prognosis [9]. The main treatment of primary amyloidosis of the breast is surgical removal [4].

**Case presentation**

A 77-year-old Japanese woman noticed a hard, nontender lump in the left lower inner part of her breast and visited the outpatient clinic for breast surgery on September 24, 2014. She had no family history of amyloidosis or breast cancer. She had hypertension, angina pectoris, and arteriosclerosis. She also had an operation history: abdominal total hysterectomy and bilateral salpingo-oophorectomy for myoma uteri at the age of 52 years.

A hard lump was palpable on the left lower inner part of her breast. The mammogram showed no mass or pleomorphic calcifications in both breasts: however, a focal asymmetric density was observed on the inner side of the left breast in the craniocaudal view, which was assessed as BI-RADS category 3 (Fig. 1). On breast ultrasonography, an irregular low echoic area was observed at the site of the lump (Fig. 2). No blood flows were seen entering the low echoic area. Elastography (elasticity imaging technique) revealed that the low echoic area was soft, a finding that is different from that of breast cancer.

An ultrasound-guided core needle biopsy was done to rule out breast cancer. Hematoxylin and eosin staining revealed eosinophilic material in the extracellular area. The specimen was positive for Congo red staining even after permanganic acid treatment, and exhibited yellow-green birefringence under polarizing microscopy.

Further examinations were carried out to rule out plasma cell myeloma, other B cell tumors, or systemic amyloidosis according to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.

The patient had neither M-protein in serum immune electrophoresis nor Bence-Jones protein in urine immune electrophoresis examination. Bone marrow aspiration was negative for plasma cell myeloma or other B cell tumors. No lymphadenopathy was seen on computed tomography. Electrocardiogram and cardiac ultrasonography showed no evidence of cardiomyopathy or amyloidosis related changes. Stomach, rectum, bone marrow, and random skin biopsies were performed and none of biopsies showed evidence of amyloidosis. Taken together, systemic amyloidosis and multiple myeloma were ruled out, and localized breast amyloidosis was highly suspected.

To make a definite diagnosis, lumpectomy was performed on December 25, 2014. Macroscopic specimens...
of the mammary gland showed abnormal white masses as arrows indicate (Fig. 3). The final pathology demonstrated homogenous eosinophilic depositions with surrounding margins of breast parenchyma (Fig. 4). The deposits were positive to Congo red and direct fast scarlet (DFS) staining after permanganic acid treatment (Fig. 4). Immunohistochemistry for AA amyloid was negative. No malignancy such as breast carcinoma, lymphoma, or plasma cell myeloma was seen.

For further immunohistochemical staining, specimens were sent to the Department of Neurology of Kumamoto University. Amyloid typing with immunohistochemistry was performed using antibodies directed against the following antigens: polyclonal rabbit anti-

Fig. 2 Ultrasonographic findings. Breast ultrasonogram showed an irregular low echoic area in the inner lower quadrant. No blood flows were present in the low echoic area, and elastography revealed that the area was soft unlike breast cancer.

Fig. 3 Macroscopic view of the specimen. The macroscopic breast specimens showed abnormal white masses as arrows indicate.
human prealbumin (TTR) (DAKO), monoclonal mouse anti-human amyloid A (clone mc1) (DAKO), polyclonal rabbit anti-human kappa light chains (DAKO), polyclonal rabbit anti-human lambda light chains (DAKO), anti-human kappa light chain monoclonal antibody, clone H16-E (Novus Biologicals), anti-IGLL5 immunoglobulin lambda-like polypeptide 5, rabbit-Poly (Novus Biologicals), rabbit monoclonal antibody [EP1368Y] to apolipoprotein A-I (Abcam), and polyclonal rabbit anti-human beta-2-microglobulin (DAKO). The resected breast tissue was positive for Congo red, IgLCk (immunoglobulin light chain kappa [polyclonal]), and Kmab (immunoglobulin light chain kappa [monoclonal]) (Fig. 5). Under polarized light, the protein exhibited yellow-green birefringence. The specimen was negative for serum amyloid A (SAA), TTR, IgLCλ (immunoglobulin light chain lambda [polyclonal]), and IGLL5 (immunoglobulin lambda-like polypeptide 5) (Fig. 5). The amyloidosis was shown to be the ALk type, which is more frequently encountered than the ALλ type [10]. The patient was free from any lymphoid malignancies or immunological disorders. Therefore, the final diagnosis was primary amyloidosis of the breast.

The patient is currently being followed-up at our institution, and has shown no evidence of disease recurrence or breast cancer at 1 year after the surgery.

This report highlights imaging and histopathological assessment of amyloidosis of the breast. Amyloidosis of
the breast is rare and should be distinguished from breast cancer, and histological assessment is necessary.

Conclusions
Localized primary amyloidosis of the breast is a very rare benign disease characterized by abnormal protein deposition in the mammary glands. This case of primary breast amyloidosis was experienced for the first time in the recent 27 years at our institution. The current standard of care of primary breast amyloidosis is surgical resection, and systemic therapy is not necessary [4]. Localized primary amyloidosis of the breast has a good prognosis; however, the patient should be followed after surgery when recurrence or malignancy occurs.

Abbreviations
AA: Amyloid type A; AL: Amyloid light chain; Ig: Immunoglobulin; TTR: Transthyretin

Acknowledgements
We thank Dr. Takeshi Terashima, who suggested consulting the Diagnosis Unit for Amyloidosis of the Department of Neurology, Kumamoto University Hospital.

Availability of data and materials
The dataset supporting the conclusions of this article is included within the article.

Authors’ contributions
WT performed the surgery, followed the patient at the outpatient clinic, and wrote the draft of the manuscript. FY participated in the surgery. SO ruled out lymphoid malignancy and systemic amyloidosis as a hematologist. ET diagnosed amyloidosis of the breast as a pathologist. TY did multiple immunohistochemical staining, and diagnosed ALκ type amyloidosis. All of the authors read the manuscript and agreed to its submission.

Competing interests
All of the authors have no potential conflicts of interest to disclose with respect to the research, authorship, and publication of this article. All authors received no financial support for the research, authorship, and publication of this article.

Ethics approval and consent to participate
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Author details
1Department of Breast Surgery, Shiga Medical Center for Adults, Shiga, Japan.
2Department of Pathology, Moriguchi Keijinkai Hospital, Osaka, Japan.
3Department of Hematology and Oncology, Shiga Medical Center for Adults, Shiga, Japan.
4Diagnosis Unit for Amyloidosis, Department of Neurology, Kumamoto University Hospital, Kumamoto, Japan.

Received: 29 June 2016 Accepted: 5 September 2016

Published online: 13 September 2016

References
1. Fernandez BB, Hernandez FJ. Amyloid tumor of the breast. Arch Pathol. 1973;95(2):102–5.
2. Charlot M, Seldin DC, O’Hara C, Skinner M, Sanchorawala V. Localized amyloidosis of the breast: a case series. Amyloid. 2011;18(2):72–5.
3. Said SM, Reynolds C, Jimenez RE, Chen B, Vrana JA, Theis JD, Dogan A, Shah SS. Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders. Mod Pathol. 2013;26(2):232–8.
4. Huerter ME, Hammadeh R, Zhou Q, Weisberg A, Riker AI. Primary amyloidosis of the breast presenting as a solitary nodule: case report and review of the literature. Ochsner J. 2014;14(2):282–6.
5. Ngendahayo P, Faverly D, Herin M. Primary breast amyloidosis presenting solely as nonpalpable microcalcifications: a case report with review of the literature. Int J Surg Pathol. 2013;21(2):177–80.
6. Shim Y, Kim MJ, Ryu HS, Park SH. Primary breast amyloidosis presenting as microlcalcifications only. Korean J Radiol. 2013;14(5):723–6.
7. O’Brien J, Ahemne S, McCormack O, Jeffers M, McInerney D. MRI features of bilateral amyloidosis of breast. Breast J. 2013;19(3):338–9.
8. Eghtedari M, Dogan BE, Gilcrease M, Roberts J, Cook ED, Yang WT. Imaging and Pathologic Characteristics of Breast Amyloidosis. Breast J. 2015;21(2):197–9. doi:10.1111/tbj.12361.
9. Gluck BS, Cabrera J, Strauss B, Ricca R, Brancaccio W, Tamsen A. Amyloid deposition of the breast. AJR Am J Roentgenol. 2000;175(6):1590.
10. Rocken C, Kronsbein H, Sletten K, Roessner A, Basler R. Amyloidosis of the breast. Virchows Arch. 2002;440(5):527–35.

Fig. 5 Immunohistochemistry. The resected breast tissue was positive for Congo red (CR), IgLκk (immunoglobulin light chain kappa [polyclonal]), and Kκ (immunoglobulin light chain kappa [monoclonal]) (Fig. 5). Under polarized light, the protein exhibited yellow-green birefringence. The specimen was negative for SAA (serum amyloid A), TTR (transthyretin), IgLκλ (immunoglobulin light chain lambda [polyclonal]), and IGLL5 (immunoglobulin lambda-like polypeptide 5)